Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, July 2000, p. 1846-1849, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
In Vitro Pharmacodynamics of the New Ketolides HMR 3004 and HMR
3647 (Telithromycin) against Chlamydia pneumoniae
I.
Gustafsson,1,*
E.
Hjelm,2 and
O.
Cars1
Departments of Infectious
Diseases1 and Clinical
Microbiology,2 University Hospital, Uppsala,
Sweden
Received 24 November 1999/Returned for modification 8 February
2000/Accepted 29 March 2000
 |
ABSTRACT |
The ketolides HMR 3004 and HMR 3647 (telithromycin) are a new class
of macrolides that have a potential clinical efficacy against
intracellular pathogens. The objectives of this study were to
investigate the MIC, minimum bactericidal concentration, and time-dependent killing of two Chlamydia pneumoniae
strains of the two ketolides. The killing effect was also
studied with a newly developed intracellular in vitro kinetic model.
Furthermore, HMR 3647 was studied for the effect of a
subinhibitory concentration of 0.5 times the MIC after a preexposure of
10 times the MIC during 12 h. The MICs for both strains were
0.0039 and 0.0156 mg/liter for HMR 3004 and HMR 3647, respectively.
Killing with 10 times the MIC was time dependent, increasing from a
1-log-unit decrease in the number of inclusions per well at 48 h
to a maximal effect of 2.8-log-unit decrease after 96 h. A
preexposure of 10 times the MIC of HMR 3647 for 12 h followed by a
subinhibitory concentration of 0.5 times the MIC increased the killing
effect to a 1.2-log-unit reduction in inclusions per well. An exposure
for 12 h gave poor reduction of inclusions, while a static dose of
10 times the MIC for 72 h showed a 2.2-log-unit reduction in
inclusions per well. In the kinetic model, a small number of inclusions
were detected after 72 h by one exposure of 10 times the MIC. Regrowth could not be detected after 120 h.
The ketolides HMR 3004 and HMR 3647 have bactericidal activity and show
a significant sub-MIC effect on the intracellular pathogen
C. pneumoniae.
 |
INTRODUCTION |
Chlamydia pneumoniae is
an obligate intracellular bacterium with a growth cycle of 72 h.
It is a widespread human pathogen causing a variety of
community-acquired respiratory tract infections in adults and children.
Several reports have indicated that chronic C. pneumoniae infections may be associated with coronary heart disease, atherosclerosis, and asthma (4, 9, 12, 17). Although the acute infection is usually self-limiting, prolonged respiratory symptoms are sometimes a feature, and in such cases C. pneumoniae has been difficult to eradicate with
antibiotics (6, 7). The optimal choice of antibiotic
treatment and dosing regimen still needs to be defined.
Pharmacodynamic studies are important tools for the determination of
optimal dosing regimens of antimicrobial agents. The ketolides, a new
class of macrolides characterized by a 3-keto function, which gives a
strong acid stability (3), act by inhibiting bacterial
protein synthesis. The ketolides have shown in vitro activity against a
broad range of respiratory tract pathogens (1, 2,
15; I. Odenholt, E. Löwdin, and O. Cars, Abstr. 39th
Intersci. Conf. Antimicrob. Agents Chemother., abstr. 540, 1999).
Although macrolide antibiotics show long postantibiotic effects, their
antibacterial activity is not concentration dependent. The major
determinant of efficacy is the time that free drug concentrations are
greater than the MIC (5). The pharmacodynamics of the
ketolides is less well known. However, significant postantibiotic
effect and postantibiotic sub-MIC effect have been demonstrated for the ketolides (Odenholt et al., 39th ICAAC). They have been shown to
accumulate in phagocytes (19, 20) and have potential
clinical efficacy against intracellular pathogens, e.g.,
Legionella spp. (18) and C. pneumoniae (16).
We have investigated the MICs, minimum bactericidal concentrations
(MBCs) and pharmacodynamics for two C. pneumoniae
strains of the two ketolides HMR 3004 and HMR 3647 with static
antibiotic concentrations. HMR 3647 was also studied with respect to
the effect of a subinhibitory concentration following a preexposure to
10 times the MIC during 12 h. Furthermore, we developed an intracellular kinetic model where the killing could be monitored for up
to 5 days.
 |
MATERIALS AND METHODS |
Cell culture.
Human epithelial cell line HEp-2 (ATCC CCL 23)
was grown in medium consisting of RPMI 1640 (Gibco BRL, Life
Technologies Ltd., Paisly, United Kingdom), 10% fetal calf serum, 20 mM HEPES, 2 mM glutamine, and 0.05% NaHCO3 at 35°C in
5% CO2. The cells were treated with trypsin and
distributed in 48-well cell culture plates at a density of
105 to 2 × 105 cells/ml and grown for
24 h to a monolayer. In the kinetic model, Falcon cell culture
inserts (pore size, 0.4 µm) were used instead of cell culture plates.
During the experiments 5% fetal calf serum was used, and the medium
was supplemented with 0.03 M glucose and 1 µg of cycloheximide
(Sigma, St. Louis, Mo.)/ml. The pH was 7.2 ± 0.2 throughout the experiments.
Preparation of antibiotics.
HMR 3004 and HMR 3647 with known
potencies were kindly provided by Hoechst-Marion-Roussel, Romainville,
France. A fresh stock solution was made before each experiment by
dissolving 10.2 mg of the substance in 10 ml of sterile distilled water
supplemented with 2 drops of glacial acetic acid.
Bacteria.
C. pneumoniae CWL 029 (ATCC VR 1310)
and a clinical strain of C. pneumoniae (G 954) derived
from a patient at the University Hospital, Uppsala, Sweden, were used.
The strains were stored at
70°C. The inoculum was adjusted
before the experiments to give 5 × 103 to
104 inclusion-forming units per ml. Unexposed controls were
included in all experiments to verify the inoculum size.
Infection of cells.
The monolayer of the HEp-2 cells was
inoculated with 0.5 ml of bacterial dilution in cell culture medium.
The plates were centrifuged for 1 h at 3,600 rpm at 30°C and
incubated for 2 h at 37°C. For this process the inserts
were placed in six-well cell culture plates. The medium was changed to
a fresh medium with 5% fetal calf serum, 1 µg of cycloheximide/ml,
0.03 M glucose, and the antibiotics in different concentrations (see below).
Determination of MIC.
Twofold serial dilutions from
0.125 to 0.00195 mg/liter were prepared in cell culture medium.
Infected cells were exposed to the different concentrations and
incubated at 35°C for 72 h. The cultures were fixed in methanol
for 10 min and stained with monoclonal antibodies for
Chlamydia spp. (Pathfinder; Kallestad Diagnostics, Chaska,
Minn.). The results were assessed with an inverted fluorescence
microscope (Ziess Diavert). MIC was defined as the lowest concentration
with a minimum of 95% reduction of inclusions compared with the
controls. The determination of MIC was made in triplicate.
Determination of MBCs.
The two strains were exposed to 5, 10, 20, 40, 80, 160, and 320 times the MIC of the antibiotics. After
72 h of incubation at 35°C, the cultures were washed three times
with phosphate-buffered saline (PBS), pH 7.2, scraped with a transfer
pipette, and passed onto a new monolayer of HEp-2 cells. After
centrifugation for 1 h at 2,500 × g at 30°C and
penetration for 2 h, the medium was changed to a fresh medium with
5% fetal calf serum, 1 µg of cycloheximide/ml, 0.03 M glucose, and
20 mg of gentamicin/liter. The plates were thereafter incubated for
another 72 h before staining and evaluation. MBC was defined as
the lowest antibiotic concentration at which no inclusions were
observed. The determination of MBC was made in triplicate.
Determination of antibiotic concentration.
Samples from the
inserts were collected during the kinetic experiments. A
microbiological agar diffusion method was used with tryptone-glucose
agar, pH 7.4. Plates were seeded with a standardized inoculum of
Sarcina lutea. Antibiotic standards and samples from the
inserts were placed into agar wells at a volume of 0.03 ml. All assays
were made in triplicate, and the plates were incubated overnight at
37°C. The limit of detection was 0.03 mg/liter, and the
correlation coefficient for the standard curves was always >0.99.
Pharmacodynamics after exposure with 10 times the MIC.
Infected cells in a 48-well cell culture plate were exposed to 10 times
the MIC of the respective antibiotic in medium. Controls without
antibiotics were included. Duplicates were made for direct staining and
passage to new cells (cf. the MBC method) after 24, 48, 72, and 96 h. The new plates were incubated for 72 h. The experiments were
made in triplicate.
The effect of a subinhibitory concentration of HMR 3647 after
previous exposure to 10 times the MIC.
Cell cultures were
infected as described above and exposed to 10 times the MIC of HMR
3647. After 12 h the medium was aspirated and the cultures were
washed three times with PBS and reexposed to a subinhibitory
concentration of 0.5 times the MIC. For comparison three sets of
cultures were included: (i) cultures exposed to 10 times the MIC during
12 h, washed three times with PBS, and covered with fresh medium
for regrowth; (ii) cultures exposed to 10 times the MIC during 72 h; and (iii) unexposed controls. After 72 h of incubation at
35°C, all cultures were stained for examination as well as washed and
passaged as described above. The experiments were made in triplicate.
In vitro kinetic model.
The model has previously been
described (11). It consists of a glass chamber with two
exits and a metal rack fitting Falcon cell culture inserts (Becton
Dickinson, Franklin Lake, N.J.) (Fig. 1).
The inserts incorporated membranes with 0.45-µm pores. The glass
chamber was connected to a pump (C6-T; Alitea AB, Stockholm, Sweden) by
Santoprene tubes (Alipren; Alitea AB). A magnet was placed in the
bottom of the glass chamber to ensure homogenous mixing of the
antibiotic. The device was placed on a magnetic stirrer in a thermostat
at 35°C with 5% CO2.
HEp-2 cells were prepared in cell culture inserts and infected with the
C. pneumoniae strains as mentioned above. The medium in
the inserts was changed to 0.4 ml of cell culture medium with the
antibiotic at a concentration of 10 times the MIC. The inserts were transferred into the glass chamber that contained the same medium.
Dilution of the antibiotic concentration was achieved by a constant
flow of fresh medium supplied by a pump. Controls were performed in
accordance with the kinetic model and yielded the same number of
inclusions as controls cultured in the companion plate for inserts. In
the experiments the latter controls were used. For HMR 3647, the
half-life inside the inserts was adjusted to 10 h. The experiment
continued for 72 h, after which two inserts of each strain were
fixed and stained. The remaining two inserts were passaged as described
above for detection of viable bacteria. The controls were treated in
the same manner. The experiments were made in triplicate.
The HMR 3004 experiments were designed in a slightly different way.
HEp-2 cells were infected as described above. The medium in the inserts
was changed to 0.4 ml of cell culture medium with 10 times the MIC of
HMR 3004 and transferred into the glass chamber that contained the same
medium. The pump was adjusted to give a half-life of approximately
5 h inside the inserts. A constant flow of fresh medium without
antibiotics continued for 48 h. Then, the inserts were removed to
a Falcon companion TC plate without antibiotics, and the experiment
continued in a static way for 72 h, for a total of 120 h.
However, the medium was changed daily. Controls without antibiotics
were grown simultaneously with inserts placed in a companion plate.
Inserts were fixed and stained for detection of C. pneumoniae after 24, 72, and 120 h. The experiments were made
in triplicate.
 |
RESULTS |
MIC and MBC.
The MICs and MBCs are presented in Table
1.
Pharmacodynamics after static exposure with 10 times the
MIC.
In the exposed cultures that were stained directly after
24, 48, 72, and 96 h, inclusions could not be detected. The
results from the passaged cultures are presented in Fig.
2. At 24 h, the mean reduction in
number of inclusions per well was only 0.5 log units, compared with the
initial inoculum. The killing effect significantly increased with the
time. After 96 h the reduction was 2.8 log inclusions/well. There
was no difference between the two ketolides. In the unexposed controls
that were passaged, almost every cell in the monolayer contained an
inclusion body and the increase in inclusion-forming units was by a
factor of 10 to 15.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 2.
Pharmacodynamics with 10 times the MIC. , CWL
029; , G 954; , control CWL 029; ×, control G 954. Shown are
means of three experiments ± standard deviations with HMR 3004 (a) and HMR 3647 (b). Incl, inclusions.
|
|
Effect of reexposure to a subinhibitory concentration with HMR
3647.
The results are exhibited in Fig.
3, where the prominent effect of a
subinhibitory concentration is obvious. Since there was no difference
between the strains, both are included in the figure.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of reexposure to a subinhibitory concentration
with HMR 3647, i.e., an initial exposure of 10 times the MIC during
12 h followed by 0.5 times the MIC. As controls, cultures
were exposed during 12 and 72 h and one culture was unexposed.
Shown are means of six experiments ± standard deviations. (a)
Direct staining after 72 h. (b) Passaged cultures after 72 h.
Incl, inclusions.
|
|
Pharmacodynamics in the in vitro kinetic model.
The results
for the passaged cultures with HMR 3647 are given in Table
2. The mean initial antibiotic
concentration was 0.15 ± 0.013 mg/liter and fell below MIC after
33 h. The initial number of inclusions was 2,500 ± 800 per
well. In the samples stained after 72 h, no inclusions could be
detected. In the passaged cultures, a reduction of 2 log units during
72 h was observed.
The results from the kinetic studies with HMR 3004 are presented in
Table 3. The initial antibiotic
concentration was 0.043 ± 0.0043 mg/liter and fell below MIC
after 17 h. A significant inhibition was observed already after
72 h, and there was no regrowth in the cultures up to 120 h.
 |
DISCUSSION |
Both ketolides showed low MICs against the two C. pneumoniae strains, which corresponds well with earlier findings
by Roblin and Hammerschlag (16). They found a MIC at which
50% of the isolates were inhibited of 0.0625 µg/ml and an MBC
ranging from 0.031 to 2 µg/ml for HMR 3647 against 19 isolates of
C. pneumoniae. The MIC is well achieved with HMR 3647 for which a dose of 800 mg gives a maximum concentration in serum of 2 mg/liter and a free concentration in serum of 0.6 mg/liter
(Hoechst-Marion-Roussel, unpublished data). The killing experiments
with a static concentration of 10 times the MIC showed that 72 to
96 h of exposure was needed to obtain a maximal bactericidal
effect. This is probably not caused by slow uptake of the drug into the
cells since it has been shown for human polymorphonuclear neutrophils
and nonphagocytizing cells that the ketolides are avidly accumulated
with high ratios of cellular to extracellular concentrations
(19, 20; I. Garcia, A. Pascual, S. Ballesta, and
E. J. Perea, Abstr. 38th Intersci. Conf. Antimicrob. Agents
Chemother., abstr. A-112, 1998). Instead, the time lag to maximal
killing may be related to the life cycle of chlamydia. Since ketolides
bind to the 50S subunit of the ribosome, the chlamydia elementary
bodies have to reorganize to the metabolically active form, reticulate
bodies, before the drug can take effect. A study by
Nyström-Rosander et al. showed the importance of sufficient antibiotic availability during the complete growth cycle
(13). A total reduction could not be expected since
elementary bodies are not susceptible to antibiotics and stay in a
latent phase even in cell cultures (8).
However, when HMR 3647 at a sub-MIC concentration of 0.5 times the MIC
was added after 12 h of exposure of 10 times the MIC, the
reduction of inclusions was significant but not as pronounced as after
a static exposure of 10 times the MIC for 72 h. The subinhibitory concentration was obviously sufficient to maintain a critical concentration of drug at the site of the ribosomes. This effect corresponds well with studies on macrolides and azithromycin, where
long postantibiotic sub-MIC effects have been described and could be
explained by the fact that the ketolides form a complex with 23S rRNA
which is 10-fold stronger than that formed by erythromycin (10,
14).
In the kinetic model, a half-life of 5 h was chosen for HMR 3004 in order to speed up the elimination and see if regrowth of chlamydia
would occur. The experiments exhibited a vast reduction of inclusions
after 72 h. Regrowth within 5 days could not be detected in the
exposed cultures. For HMR 3647, the half-life was adjusted to 10 h, which corresponds with the elimination half-life of the drug found
in humans. These experiments were run for 72 h. A reduction of 2 log units was obtained with one initial dose of 10 times the MIC, as
determined by transfer to new cells, which indicates prolonged
bactericidal effect even when the concentration fell below the MIC.
Our results have shown that the ketolides HMR 3004 and HMR 3647 have
bactericidal activity and show a significant sub-MIC effect on the
intracellular pathogen C. pneumoniae.
 |
ACKNOWLEDGMENT |
This work was supported by grants from Hoechst-Marion-Roussel,
Romainville, France.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Clinical Microbiology, University Hospital, SE-751 85 Uppsala, Sweden. Phone: 46 (18) 66 39 10. Fax: 46 (18) 55 91 57. E-mail:
ingegerd.gustafsson{at}medsci.uu.se.
 |
REFERENCES |
| 1.
|
Barry, A. L.,
P. C. Fuchs, and S. D. Brown.
1998.
In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae.
Antimicrob. Agents Chemother.
42:2138-2140[Abstract/Free Full Text].
|
| 2.
|
Boswell, F. J.,
J. M. Andrews, and R. Wise.
1998.
Pharmacodynamic properties of HMR 3647, a new ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect.
J. Antimicrob. Chemother.
41:149-153[Abstract/Free Full Text].
|
| 3.
|
Bryskier, A.,
C. Agouridas, and J. F. Chantot.
1997.
Ketolides: new semi-synthetic 14-membered ring macrolide, p. 39-50.
In
S. H. Zinner, L. S. Young, J. F. Acar, and H. C. Neu (ed.), Expanding indications for the new macrolides, azalides and streptogramins. Marcel Dekker Inc., New York, N.Y.
|
| 4.
|
Campbell, L. A.,
E. R. O'Brien,
A. L. Cappuccio,
C. Kuo,
S. Wang,
D. Stewart,
D. L. Patton,
P. K. Cummings, and J. T. Grayston.
1995.
Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues.
J. Infect. Dis.
172:585-588[Medline].
|
| 5.
|
Carbon, C.
1998.
Pharmacodynamics of macrolides, azalides and streptogramins: effect on extracellular pathogens.
Clin. Infect. Dis.
27:28-32[Medline].
|
| 6.
|
Falck, G.,
J. Gnarpe, and H. Gnarpe.
1996.
Persistent Chlamydia pneumoniae infection in a Swedish family.
Scand. J. Infect. Dis.
28:271-273[Medline].
|
| 7.
|
Falck, G.,
I. Engstrand,
A. Gad,
J. Gnarpe,
H. Gnarpe, and A. Laurila.
1997.
Demonstration of Chlamydia pneumoniae in patients with chronic pharyngitis.
Scand. J. Infect. Dis.
29:585-589[Medline].
|
| 8.
|
Gnarpe, J.,
K. Eriksson, and H. Gnarpe.
1996.
In vitro activities of azithromycin and doxycyclin against 15 isolates of Chlamydia pneumoniae.
Antimicrob. Agents Chemother.
40:1843-1845[Abstract].
|
| 9.
|
Hahn, D. L.,
R. W. Dodge, and R. Golubjatnikov.
1991.
Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis and adult-onset asthma.
JAMA
226:225-230.
|
| 10.
|
Hansen, L. H.,
P. Mauvais, and S. Douthwaite.
1999.
The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA.
Mol. Microbiol.
31:623-631[CrossRef][Medline].
|
| 11.
|
Hultén, K.,
R. Rigo,
I. Gustafsson, and L. Engstrand.
1996.
New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms.
Antimicrob. Agents Chemother.
40:2727-2731[Abstract].
|
| 12.
|
Nyström-Rosander, C.,
S. Thelin,
E. Hjelm,
O. Lindquist,
C. Påhlsson, and G. Friman.
1997.
High incidence of Chlamydia pneumoniae in sclerotic heart valves of patients undergoing aortic valve replacement.
Scand. J. Infect. Dis.
29:361-365[Medline].
|
| 13.
|
Nyström-Rosander, C.,
K. Hultén,
I. Gustafsson,
O. Cars,
L. Engstrand, and E. Hjelm.
1997.
Susceptibility of Chlamydia pneumoniae to azithromycin and doxycyclin: methodological aspects on the determination of minimal inhibitory and minimal bactericidal concentrations.
Scand. J. Infect. Dis.
29:513-516[Medline].
|
| 14.
|
Odenholt-Tornqvist, I,
E Löwdin, and O. Cars.
1995.
Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin and azithromycin on respiratory tract pathogens.
Antimicrob. Agents Chemother.
39:221-226[Abstract].
|
| 15.
|
Reinert, R. R.,
A. Bryskier, and R. Lütticken.
1998.
In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany.
Antimicrob. Agents Chemother.
42:1509-1511[Abstract/Free Full Text].
|
| 16.
|
Roblin, P. M., and R. Hammerschlag.
1998.
In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.
Antimicrob. Agents Chemother.
42:1515-1516[Abstract/Free Full Text].
|
| 17.
|
Saikku, P.,
M. Leinonen,
K. Mattila,
M. R. Ekman,
M. S. Nieminen,
P. H. Mäkelä,
J. K. Huttunen, and V. Valtonen.
1988.
Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.
Lancet
ii:983-986.
|
| 18.
|
Schulin, T.,
C. B. Wennersten,
M. J. Ferraro,
R. C. Moellering, Jr., and G. M. Eliopoulos.
1998.
Susceptibilities of Legionella spp. to newer antimicrobials in vitro.
Antimicrob. Agents Chemother.
42:1520-1523[Abstract/Free Full Text].
|
| 19.
|
Vazifeh, D.,
H. Abdelghaffar, and M. T. Labro.
1997.
Cellular accumulation of the ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin.
Antimicrob. Agents Chemother.
41:2099-2107[Abstract].
|
| 20.
|
Vazifeh, D.,
A. Preira,
A. Bryskier, and T. Labro.
1998.
Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils.
Antimicrob. Agents Chemother.
42:1944-1951[Abstract/Free Full Text].
|
Antimicrobial Agents and Chemotherapy, July 2000, p. 1846-1849, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.